Organogenesis (ORGO) Competitors $5.04 +0.18 (+3.70%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$5.03 -0.01 (-0.20%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. CGON, ALVO, CPRX, TARS, IDYA, OCUL, MLYS, IBRX, DNLI, and IRONShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Denali Therapeutics (DNLI), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Mineralys Therapeutics ImmunityBio Denali Therapeutics Disc Medicine Organogenesis (NASDAQ:ORGO) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings. Which has more risk and volatility, ORGO or CGON? Organogenesis has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Is ORGO or CGON more profitable? Organogenesis has a net margin of -1.92% compared to CG Oncology's net margin of -15,945.17%. Organogenesis' return on equity of -0.37% beat CG Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.92% -0.37% -0.20% CG Oncology -15,945.17%-19.37%-18.72% Do analysts recommend ORGO or CGON? Organogenesis currently has a consensus target price of $7.50, suggesting a potential upside of 48.81%. CG Oncology has a consensus target price of $53.91, suggesting a potential upside of 62.57%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67CG Oncology 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Do institutionals & insiders hold more shares of ORGO or CGON? 49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by company insiders. Comparatively, 7.4% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to ORGO or CGON? In the previous week, CG Oncology had 22 more articles in the media than Organogenesis. MarketBeat recorded 25 mentions for CG Oncology and 3 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.55 beat CG Oncology's score of 0.68 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CG Oncology 7 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Which has better earnings and valuation, ORGO or CGON? Organogenesis has higher revenue and earnings than CG Oncology. Organogenesis is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$482.04M1.33$860K-$0.14-36.00CG Oncology$1.14M2,217.94-$88.04M-$1.77-18.73 SummaryOrganogenesis beats CG Oncology on 10 of the 17 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$616.53M$2.55B$5.78B$10.07BDividend YieldN/A56.65%5.69%4.62%P/E Ratio-36.0023.7675.0426.20Price / Sales1.33564.68469.7391.86Price / Cash23.29169.2537.0859.91Price / Book2.415.3912.236.28Net Income$860K$32.95M$3.29B$270.85M7 Day Performance0.80%2.61%1.53%3.58%1 Month Performance3.07%9.87%7.86%6.67%1 Year Performance93.10%1.49%63.05%27.74% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.0251 of 5 stars$5.04+3.7%$7.50+48.8%+96.9%$616.53M$482.04M-36.00950Positive NewsCGONCG Oncology2.2121 of 5 stars$33.69+1.9%$53.91+60.0%-9.2%$2.52B$1.14M-19.0361High Trading VolumeALVOAlvotech3.2912 of 5 stars$8.16-2.0%$14.00+71.6%-25.2%$2.51B$491.98M35.481,032Positive NewsShort Interest ↓CPRXCatalyst Pharmaceuticals4.9211 of 5 stars$20.08-1.0%$33.20+65.3%+4.1%$2.48B$491.73M12.1780Positive NewsInsider TradeTARSTarsus Pharmaceuticals2.617 of 5 stars$56.89-1.3%$66.67+17.2%+63.1%$2.43B$182.95M-24.4250Positive NewsInsider TradeIDYAIDEAYA Biosciences4.008 of 5 stars$23.39-13.9%$45.77+95.7%-31.1%$2.38B$7M-6.1780Positive NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeOCULOcular Therapeutix3.8588 of 5 stars$12.71-6.5%$17.20+35.3%+51.3%$2.37B$63.72M-9.93230Positive NewsMLYSMineralys Therapeutics3.0264 of 5 stars$35.93+3.2%$36.60+1.9%+219.2%$2.31BN/A-10.0928Analyst ForecastIBRXImmunityBio2.3785 of 5 stars$2.41+0.4%$10.75+346.1%-28.5%$2.27B$14.74M-5.02590Analyst ForecastDNLIDenali Therapeutics4.4037 of 5 stars$15.50+0.5%$33.62+116.9%-45.3%$2.26B$330.53M-5.54430Positive NewsIRONDisc Medicine3.2931 of 5 stars$61.91+1.9%$98.30+58.8%+24.3%$2.11BN/A-13.8530Positive NewsHigh Trading Volume Related Companies and Tools Related Companies CG Oncology Alternatives Alvotech Alternatives Catalyst Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives Ocular Therapeutix Alternatives Mineralys Therapeutics Alternatives ImmunityBio Alternatives Denali Therapeutics Alternatives Disc Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGO Stock Alerts